eversyn

eversyn GmbH is a spin-off of the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg, Germany, founded and run by current and former Max Planck scientists and business professionals. The company has developed a proprietary enzymatic platform for cell-free biosynthesis of highly complex glycans at low cost and unprecedented scale, including human milk oligosaccharides (HMOs) and nucleotide sugars used in nutrition and biopharmaceuticals. eversyn's technology addresses the challenge that nucleotide sugars are 100x more expensive than gold by weight, making HMOs commercially inaccessible. The company has filed multiple patents and published peer-reviewed research. In March 2025, eversyn secured €1.6 million in seed funding to accelerate its technology platform.